SCHEMBL652215

SCHEMBL652215

CCN(CC)CCOc1ccc(/N=C2/NC(=O)/C(=C/c3cnc(NC(=O)C4CC4)s3)S2)c(C(F)(F)F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.36
ABL1 P00519 3/20 0.34
DYRK3 O43781 1/20 0.34
MAPT P10636 3/20 0.33
PTPN7 P35236 2/20 0.33
DUSP3 P51452 2/20 0.33
PTPN12 Q05209 2/20 0.33
PTPN22 Q9Y2R2 2/20 0.33
LYN P07948 2/20 0.33
LCK P06239 1/20 0.33
TXK P42681 1/20 0.32
JAK3 P52333 1/20 0.32
ITK Q08881 1/20 0.32
DHODH Q02127 1/20 0.32
POLB P06746 1/20 0.32
PTPN5 P54829 1/20 0.32
PTPN11 Q06124 1/20 0.32
SRC P12931 1/20 0.32
BTK Q06187 1/20 0.32
CHEK1 O14757 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL653370 0.90 MAPT (0.40) HPGDABL1MAPTPTPN7DUSP3
SCHEMBL698337 0.84 PTPN7 (0.36) HPGDABL1MAPTPTPN7DUSP3
SCHEMBL10176526 0.84 KDR (0.39) ABL1DYRK3TXKJAK3ITK
SCHEMBL10176525 0.83 ABL1 (0.36) HPGDABL1DYRK3MAPTPTPN7
SCHEMBL650221 0.83 ABL1 (0.36) HPGDABL1DYRK3MAPTPTPN7
SCHEMBL649652 0.83 RNASEL (0.40) HPGDABL1DYRK3
SCHEMBL652415 0.83 MAPT (0.41) HPGDABL1MAPTPTPN7DUSP3
SCHEMBL699754 0.83 KDR (0.38) ABL1DYRK3TXKJAK3ITK
SCHEMBL703259 0.82 MEN1 (0.38) HPGDMAPTPTPN7PTPN12PTPN22
SCHEMBL653897 0.81 MAPT (0.40) HPGDABL1MAPTPTPN7DUSP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 HPGD 3970/4885ABL1 978/4885DYRK3 1808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.